文献速递膀胱癌与上尿路尿路上皮癌

评估靶向成纤维细胞生长因子受体抑制治疗局限性上尿路尿路上皮癌耐受性与活性的1b期试验

Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.
PubMed 文献 · J Urol · 2024-04-04

这项1b期试验纳入14例局限性上尿路尿路上皮癌患者,给予英菲格拉替尼125 mg每日一次口服,连用21天(28天为一周期),共2个周期。2例(14.3%)出现终止治疗的毒性,低于预设停止边界;9例FGFR3变异患者中6例(66.7%)出现缓解,缓解者中位肿瘤缩小67%。结论认为FGFR抑制耐受良好且在FGFR3变异肿瘤中有显著活性,支持设计生物标志物驱动的2期试验。

要点

  • 英菲格拉替尼125 mg每日一次口服×21天(28天周期)共2周期,14.3%出现终止治疗毒性。
  • 9例FGFR3变异患者中6例(66.7%)缓解,缓解者中位肿瘤缩小67%。
  • 5例原计划肾输尿管切除/输尿管切除者中3例转为输尿管镜。

核心结论

  • 在局限性上尿路尿路上皮癌中,FGFR抑制耐受良好且在FGFR3变异肿瘤中有显著活性。
  • 相当比例参与者得以保留肾脏。
  • 这些数据支持在该临床需求显著未满足人群中设计生物标志物驱动的FGFR3抑制2期试验。

研究设计与样本

  • 生物标志物指导的术前1b期试验(NCT04228042),纳入拟行输尿管镜或肾输尿管切除/输尿管切除的局限性上尿路尿路上皮癌患者,计划入组20例。
  • 给予英菲格拉替尼125 mg每日一次口服×21天(28天为一周期),共2个周期。
  • 采用贝叶斯设计及预设停止边界监测耐受性;主要终点为耐受性,次要终点为基于肿瘤定位的客观缓解。
  • 采用NovaSeq 6000实体瘤 panel 进行靶向测序。

主要发现

  • 2021年5月至2022年11月共入组14例,随后因所有英菲格拉替尼肿瘤试验终止而关闭试验。
  • 2例(14.3%)出现终止治疗的毒性,远低于停止阈值。
  • 9例FGFR3变异患者中6例(66.7%)出现缓解;缓解者中位肿瘤缩小67%。
  • 5例最初计划行肾输尿管切除/输尿管切除的患者中3例转为输尿管镜。
  • 缓解者中位随访24.7个月(14.9-28.9)。

关键数值与推荐

  • 英菲格拉替尼125 mg每日一次口服×21天(28天为一周期),共2个周期。
  • 终止治疗毒性2例(14.3%),低于预设停止边界。
  • FGFR3变异患者9例中6例(66.7%)缓解,缓解者中位肿瘤缩小67%。

临床怎么用

  • 原文结论认为FGFR抑制耐受良好且在FGFR3变异肿瘤中有显著活性,并支持设计生物标志物驱动的2期试验,未给出临床常规使用推荐。

局限性

  • 试验因所有英菲格拉替尼肿瘤试验终止而提前关闭,仅入组14例(计划20例)。
  • 原文结论指出这些数据支持设计2期试验,提示需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We initiated a biomarker-informed preoperative study of infigratinib, a fibroblast growth factor receptor (FGFR) inhibitor, in patients with localized upper tract urothelial carcinoma (UTUC), a population with high unmet needs and tumor with a high frequency of FGFR3 alterations. MATERIALS AND METHODS: Patients with localized UTUC undergoing ureteroscopy or nephroureterectomy/ureterectomy were enrolled on a phase 1b trial (NCT04228042). Once-daily infigratinib 125 mg by mouth × 21 days (28-day cycle) was given for 2 cycles. Tolerability was monitored by Bayesian design and predefined stopping boundaries. The primary endpoint was tolerability, and the secondary endpoint was objective response based on tumor mapping, done after endoscopic biopsy and post-trial surgery. Total planned enrollment: 20 patients. Targeted sequencing performed using a NovaSeq 6000 solid tumor panel. RESULTS: From May 2021 to November 2022, 14 patients were enrolled, at which point the trial was closed due to termination of all infigratinib oncology trials. Two patients (14.3%) had treatment-terminating toxicities, well below the stopping threshold. Responses occurred in 6 (66.7%) of 9 patients with FGFR3 alterations. Responders had median tumor size reduction of 67%, with 3 of 5 patients initially planned for nephroureterectomy/ureterectomy converted to ureteroscopy. Median follow-up in responders was 24.7 months (14.9-28.9). CONCLUSIONS: In this first trial of targeted therapy for localized UTUC, FGFR inhibition was well tolerated and had significant activity in FGFR3 altered tumors. Renal preservation was enabled in a substantial proportion of participants. These data support the design of a biomarker-driven phase 2 trial of FGFR3 inhibition in this population with significant unmet clinical needs.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Matin SF, Adibi M, Shah AY, et al. Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma. J Urol. 2024. PMID: 38573872. doi:10.1097/JU.0000000000003928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。